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Abstract
Background: Financial constraints, social taboos and beliefs in alternative medicine are common reasons for delaying or 
not considering treatment for hepatitis C in India. The present study was planned to analyze the impact of non-banking 
interest free loan facility in patients affected with hepatitis C virus (HCV) in North India.
Methods: This one year observational, retrospective study was conducted in Department of Gastroenterology (January 
2012-December 2013), Dayanand Medical College and Hospital Ludhiana, to evaluate the impact of program titled 
“Sambhav” (which provided non-banking financial assistance and counselor services) on treatment initiation and 
therapeutic compliance in HCV patients. Data of fully evaluated patients with chronic hepatitis, and/or cirrhosis due to 
HCV infection who were treated with Peginterferon alfa and ribavirin (RBV) combination during this duration (2012-
2013) was collected from patient medical records and analyzed. In the year 2012, eligible patients who were offered 
antiviral treatment paid for treatment themselves, while in 2013, ‘Sambhav’ program was launched and this provided 
interest free financing by non-banking financial company (NBFC) for the treatment of HCV in addition to free counselor 
services for disease management. The treatment initiation and compliance rates were compared between the patients (n 
= 585) enrolled in 2013 who were offered ‘Sambhav’ assistance and those enrolled in 2012 (n = 628) when ‘Sambhav’ 
was not available.
Results: Introduction of Sambhav program improved the rates of treatment initiation (59% in 2013 vs. 51% in 2012, 
P = .004). Of the 585 eligible patients offered ‘Sambhav’ assistance in 2013, 233 patients (39.8%) applied but 106/233 
(45.4%) received assistance. Antiviral therapy was started in 93/106 (87.7%) of these patients, while only 52 (42.5%) of 
127 patients whose applications were rejected underwent treatment. Compliance to antiviral therapy also improved with 
the introduction of ‘Sambhav’ program (87.7% vs. 74.1%, P = .001).
Conclusion: ‘Sambhav’ program had significant impact on the initiation of antiviral therapy by overcoming the financial 
hurdles. The free counselor services helped to mitigate social taboos and imparted adequate awareness about the disease 
to the patients. Initiatives like ‘Sambhav’ can be utilized for improving healthcare services in developing countries, 
especially for chronic diseases.
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Implications for policy makers
• Heavy financial burden required for treatment of chronic diseases is a major deterrent for seeking medical aid.
• Lack of disease awareness also contributes towards delayed treatment in developing countries. 
Implications for the public
Hepatitis C infection is the most common cause of chronic liver disease. The severity of hepatitis C, its progression, and response to therapy may 
vary depending on the genotype.
The common modes of transmission of hepatitis C infection are blood transfusion, IV drug use, unsafe therapeutic injection, and health care-related 
procedures. In India blood transfusion and unsafe injection practices are predominant modes of hepatitis C transmission.
Key Messages 
Politics nd Power in Global He lth: The Constituting Role 
of Conflicts
Comment on “Navigating Between Stealth Advocacy and Unconscious Dogmatism: The 
Challenge of Rese rchi g the Norms, Politic  and Power of Glob l Health”
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Abstract
In a recent article, Gorik Ooms has drawn attention to the normative underpinnings of the politics of 
global health. We claim that Ooms is indirectly submitting to a liberal conception of politics by framing 
the politics of global health as a question of individual morality. Drawing on the theoretical works of 
Chantal Mouffe, we introduce a conflictual concept of the political as an alternative to Ooms’ conception. 
Using controversies surrounding medical treatment of AIDS patients in developing countries as a case we 
underline the opportunity for political changes, through political articulation of an issue, and collective 
mobilization based on such an articulation.
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In a recent contribution to the ongoing debate about the role of p wer in global health, Gorik Ooms emphasizes the normative underpinnings of global health politics. 
He identifies three related problems: (1) a lack of agreement 
among global health scholars about their normative premises, 
(2) a lack of agreement between global health scholars and 
policy-makers regarding the normative premises underlying 
policy, and (3) a lack of willingness among scholars to 
clearly state their normative premises and assumptions. This 
confusion is for Ooms one of the explanations “why global 
health’s policy-makers are not implementing the knowledge 
generated by global health’s empirical scholars.” He calls 
for greater unity between scholars and between scholars 
and policy-makers, concerning the underlying normative 
premises and greater openness when it comes to advocacy.1
We commend the effort to reinstate power and politics in 
global health and agree that “a purely empirical evidence-based 
approach is a fiction,” and that such a view risks covering up 
“the role of politics and power.” But by contrasting this fiction 
with global health research “driven by crises, hot issues, and 
the concerns of organized interest groups,” as a “path we are 
trying to move away from,” Ooms is submitting to a liberal 
conception of politics he implicitly criticizes the outcomes 
of.1 A liberal view of politics evades the constituting role of 
conflicts and reduces it to either a rationalistic, economic 
calculation, or an individual question of moral norms. This 
is echoed in Ooms when he states that “it is not possible to 
discuss the politics of global health without discussing the 
normative premises behind the politics.”1 But what if we 
take the political as the primary level and the normative as 
se ondary, or derived from the political?
That is wh t w  will try to do here, by introducing an 
alternative conceptualization of the political and hence free 
us from the “false dilemma” Ooms also wants to escape. 
“Although constructivists have emphasized how underlying 
normative structures constitute actors’ identities and 
interests, they have rarely treated these normative structures 
themselves as defined and infused by power, o  emphasized 
how constitutive effects also are expressions of power.”2 This 
is the starting point for the political theorist Chantal Mouffe, 
and her response is to develop an ontological conception of 
the political, where “the political belongs to our ontological 
condition.”3 According to Mouffe, society is instituted 
through conflict. “[B]y ‘the political’ I mean the dimension of 
antagonism which I take to be constitutive of human societies, 
while by ‘politics’ I mean the set of practices and institutions 
through which an order is created, organizing human 
coexistence in the context of conflictuality provided by the 
political.”3 An issue or a topic needs to be contested to become 
political, and such a contestation concerns public action and 
creates a ‘we’ and ‘they’ form of collective identification. But 
the fixation of social relations is partial and precarious, since 
antagonism is an ever present possibility. To politicize an issue 
and be able to mobilize support, one needs to represent the 
world in a conflictual manner “with opposed camps with 
which people can identify.”3 
Ooms uses the case of “increasing international aid spending 
on AIDS treatment” to illustrate his point.1 He frames the 
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 a rece t c tri ti  t  t e g i g e ate a t t e 
r le f er i  gl al ealt , rik s e asizes 
t e r ative er i i gs f gl al ealt  litics. 
e i e tifi s t ree relat  r l s: (1) a lack f agree e t 
a g gl al ealt  sc lars a t t eir r ative re ises, 
(2) a lack f agree e t et ee  gl al ealt  sc lars a  
licy- akers regar i g t e r ative re ises erlyi g 
licy, a  (3) a lack f illi g ess a g sc lars t  
clearly state t eir r ative re ises a  ass ti s. is 
c f si  is f r s e f t e ex la ati s “ y gl al 
ealt ’s licy- akers are t i le e ti g t e k le ge 
ge erate  y gl al ealt ’s e irical sc lars.” e calls 
f r greater ity et ee  sc lars a  et ee  sc lars 
a  licy- akers, c cer i g t e erlyi g r ative 
re ises  gr ater ess e  it c es t  a v cacy.1
e c e  t e eff rt t  rei state er a  litics i  
gl al ealt  a  agree t at “a rely e irical evi e ce- ase  
a r ac  is a ficti ,” a  t at s c  a vie  risks c veri g  
“t e r le f litics a  er.” t y c trasti g t is ficti  
it  gl al ealt  researc  “ rive  y crises, t iss es, a  
t e c cer s f rga ize  i terest gr s,” as a “ at  e are 
tryi g t  ve a ay fr ,” s is s itti g t  a li eral 
c ce ti  f litics e i licitly criticizes t e tc es 
f.1  li eral vie  f litics eva es t e c stit ti g r le f 
c flicts a  re ces it t  eit er a rati alistic, ec ic 
calc lati , r a  i ivi al esti  f ral r s. is 
is ec e  i  s e  e states t at “it is t ssi le t  
isc ss t e litics f gl al ealt  it t isc ssi g t e 
r ative re ises e i  t e litics.”1 t at if e 
take t e litical as t e ri ary level a  t e r ative as 
se ary, r erive  fr  t e litical?
at is t  ill try t   ere, y i tr ci g a  
alter  c ce t alizati  f t e litical a  e ce free 
s fr  t e “false ile a” s als  a ts t  esca e. 
“ lt g  c str ctivists ave e asize   erlyi g 
r ative str ct res c stit te act rs’ i e tities a  
i terests, t ey ave rarely treate  t ese r ative str ct res 
t e selves as efi e  a  i f se  y er, r e asize  
 c stit tive effects als  are ex ressi s f er.”2 is 
is t e starti g i t f r t e litical t e rist a tal ffe, 
a  er res se is t  evel  a  t l gical c ce ti  f 
t e litical, ere “t e litical el gs t  r t l gical 
c iti .”3 cc r i g t  ffe, s ciety is i stit te  
t r g  c flict. “[ ]y ‘t e litical’ I ea  t e i e si  f 
a tag is  ic  I take t  e c stit tive f a  s cieties, 
ile y ‘ litics’ I ea  t e set f ractices a  i stit ti s 
t r g  ic  a  r er is create , rga izi g a  
c existe ce i  t e c text f c flict ality r vi e  y t e 
litical.”3  iss e r a t ic ee s t  e c teste  t  ec e 
litical, a  s c  a c testati  c cer s lic acti  a  
creates a ‘ e’ a  ‘t ey’ f r  f c llective i e tificati . t 
t e fixati  f s cial relati s is artial a  recari s, si ce 
a tag is  is a  ever rese t ssi ility.  liticize a  iss e 
a  e a le t  ilize s rt, e ee s t  re rese t t e 
rl  i  a c flict al a er “ it  se  ca s it  
ic  e le ca  i e tify.”3 
s ses t e case f “i creasi g i ter ati al ai  s e i g 
 I S treat e t” t  ill strate is i t.1 e fra es t e 
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Introduction
Provision of healthcare security or healthcare insurance 
in developing countries like India continues to be one of 
the most important unresolved policy issues. A majority 
of the patients affected with chronic illnesses spend a large 
percentage of their income on health-related expenditure, 
especially when they seek in-patient care for major health 
issues. Further, the high incidence of sickness cuts into their 
budget in two different ways: they need to spend large amount 
of money for treatment and are unable to earn money while 
they are under treatment. It is estimated that at least 24% of 
all Indians hospitalized fall below the poverty line because 
of hospitalization and out of pocket spending on hospital 
care.1-4
Hepatitis C virus (HCV) infection is estimated to affect 0.5%–
1.5% of Indian population showing much higher prevalence 
in some areas of northeast India, in some tribal populations 
and in certain parts of Punjab. The long-term implications of 
HCV infection are variable, ranging from minimal histological 
changes to extensive fibrosis and cirrhosis with or without 
hepatocellular carcinoma.5 The primary goal of HCV therapy 
is to cure the infection. In India approximately 14 million 
patients are affected with chronic hepatitis C (CHC), but 
treatment rate is as low as 1% when compared with diagnosis 
rate of 6%. The lack of disease awareness, its consequences 
and financial constraints are the major barriers which prevent 
successful treatment outcomes.6
Until 2011, the combination of pegylated interferon (PEG-
IFN) and ribavirin (RBV) for 24 or 48 weeks was the standard 
of care for CHC. With this regimen, sustained virological 
response (SVR) rates were higher in patients infected 
with HCV genotypes 2, 3, 5, and 6 (up to about 80%) and 
intermediate SVR rates (40%–50%) were achieved in those 
with HCV genotypes 1 and 4. During the study period 2012-
2013, the standard of care was peg-interferon with RBV and 
the average cost of the entire treatment was between 150 000-
300 000 INR (US$2345-4695).5-7 The newer direct acting 
antivirals (DAAs) which are highly efficacious and cheaper 
were introduced in India after the study period, ie, after 
2014.8 The prevalence of CHC in Punjab and Haryana has 
been reported to be as high as 4%. Treatment with Peg-IFN 
alpha and RBV was costly, and only 0.1% of the patients could 
afford treatment. In addition to financial constraints, fear 
of side effects, several myths about HCV among the people 
and faith in alternative medicines limited the acceptance of 
therapy with anti-virals. 
To address these issues, ‘Sambhav’ program was launched 
in 2013, offering interest free loan for the needy patients for 
the HCV treatment, monitoring compliance and addressing 
myths through counselor services. We hereby present our 
analysis of impact of this program on the initiation of 
treatment and subsequent compliance with Peg-IFN and RBV 
in patients with CHC. 
Methods 
Setting 
This was an observational, retrospective study conducted 
between January 2012 and December 2013 in Department of 
Gastroenterology, Dayanand Medical College and Hospital 
(DMC & H), Ludhiana, Punjab, India. The aim of the study 
was to evaluate impact of financial support on treatment access 
and compliance in CHC. During this period the available 
treatment for patients with chronic hepatitis or cirrhosis due 
to HCV included PEG-IFN alpha in combination with RBV. 
The acceptance and compliance to antiviral treatment in the 
patients treated for CHC in 2012 (with self-payment) and 2013 
(with support from ‘Sambhav’ program) was retrospectively 
analyzed.
The “Sambhav” Program
The ‘Sambhav’ (Hindi word, meaning it is possible) program, 
launched in 2013, was a novel collaboration between a hospital 
(Dayanand Medical College and Hospital Ludhiana), Merck 
pharmaceutical company (MSD) and a financing institution 
(Fullereton, India) to address the needs of the patients with 
CHC. This program had two components: first; financing by 
way of loan and second; provision of free counseling services 
for proper disease management.
The main objective of Sambhav program was to overcome 
cash flow issues, remove any excess financial burden on 
patients choosing this program and remove patient liability 
if there was no cure. Under the financing program, eligible 
patients got an interest free, unsecured financing from a non-
banking financial company (NBFC), for the treatment of 
hepatitis C. The loan provided under the financing scheme 
was payable over period of 2-4 years (depending upon the 
affordability and preference of the patients) and the payment 
was to be done in the form of equated monthly installments 
(EMIs), (calculated using Fullerton software, then rebate given 
toward end of loan). The loans were provided to traditionally 
difficult to fund profiles eg, farmers and shop owners etc. 
Other incentives included zero extra charge and easier loan 
terms, simplified documentation requirements and waiver of 
the outstanding EMIs in case of non-cure (defined as drug 
non-responders at 12 weeks and patients not achieving end 
of treatment response [ETR] or SVR after completion of 
therapy). 
For disease management the main objectives of HCV 
counsellors were to optimize the chances of achieving cure 
of CHC by removing myths, if any, and to help patients 
understand the importance of treatment and completing the 
full course. Free counselor services, ‘Saarthi’ (Sanskrit word for 
charioteer, signifying the one who helps one to pass through 
an obstacle) were started to implement this. These included 
in-person and phone counseling services, free diagnostic tests 
and assistance in procurement of the loan (Figure). 
Patients and Treatment
All patients who had been found to be HCV positive had 
been assessed for the status of liver disease (liver biochemical 
tests, ultrasonography and biopsy, if indicated) and viral 
characteristics (HCV RNA levels and genotype). Those found 
to be fit for therapy (patients with advanced liver disease, 
depression, cardiopulmonary disease, renal failure were 
excluded) had been offered PEG-IFN and RBV. Those who 
started anti-viral therapy had been monitored for compliance, 
Sood et al
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efficacy and adverse events. Compliance of treatment was 
noted as per patients statements. The patients were followed 
up every 4 weeks in clinic of the gastroenterologist and were 
weekly monitored for compliance and treatment related 
queries by the counselor either personally or telephonically. 
In the year 2012, the patients accepting treatment had to pay 
for the treatment themselves, while financial assistance and 
free counseling was provided by the Sambhav program in 
2013. 
In 2013, the confirmed cases for HCV requiring treatment 
with PEG-IFN and RBV were introduced to the ‘Sambhav’ 
program by the counselor/treating physician. Patients offered 
‘Sambhav’ program included (a) All confirmed patients 
(age <60 years) for HCV requiring treatment (b) monthly 
documented income >INR 10 000 (US$157). The other 
prerequisites for financial assistance included (i) one loan per 
family; (ii) minimum amount of loan INR 100 000 (US$1565); 
(iii) payment of an interest if loan repayment tenure was 
more than 2-4 years. The exclusion criteria were (a) age >60 
years (b) single patients (widow/widower, divorcee), and (c) 
monthly documented income <INR 10 000 (US$157).
For analysis the patients were divided into 2 groups:
•	 Group A: CHC patients presenting to the DMC & H after 
launch of ‘Sambhav’ (in year 2013).
♦	 Group A1: Patients who received the ‘Sambhav’ 
assistance.
♦	 Group A2: Patients who did not receive the ‘Sambhav’ 
assistance either because they did not apply or because 
their application was rejected. 
•	 Group B: Confirmed CHC patients presenting to the 
clinics prior to SAMBHAV (in year 2012). A designated 
CRO (Central Record Officer) captured, checked, 
stored and analyzed the data. CRO followed internal 
SOPs (Standard operating procedures). The data was 
transferred to the principal investigator after termination 
of the study. Quality control audits of all key safety and 
effectiveness data in the database were made prior to 
locking the database. 
Data Analysis 
Data analysis was done using SPSS and was summarized 
using descriptive summary statistics (mean and standard 
deviation). Bi-variate analyses were performed to test the 
relationship between the background characteristics of the 
patients and the outcome variables such as the HCV treatment 
initiation and compliance using chi-square tests. P values 
<.05 were considered to indicate statistical significance. The 
multivariate logistic regression was used in order to control 
for the important background factors to verify the bi-variate 
relationships between the interest free loan through ‘Sambhav’ 
and the outcome variables such as the HCV treatment 
initiation and compliance.
Results
In 2012 a total of 628 patients (self-payment, no ‘Sambhav’ 
program) and in 2013, 585 patients (under ‘Sambhav’ 
program) were included. The baseline characteristics of the 
patients are listed in Table 1.
Treatment for CHC was initiated in 318/628 patients (51%) 
in 2012. All these patients had to make the payment for anti-
viral therapy from their own pocket. After the launch of 
‘Sambhav’ program in 2013, the rate of treatment initiation 
significantly increased to 59% (344/585, P = .004), however 
there was no significant change in the duration of treatment 
or rates of compliance to therapy (Table 2).
Of the 233/585 (39.8%) of the patients who applied for the 
 
6 
 
the year 2012, the patients accepting treatment had to pay for the treatment themselves, while 1 
financial assistance and free counseling was provided by the Sambhav program in 2013.  2 
In 2013, the confirmed cases for HCV requiring treatment with Peg-IFN and RBV were introduced 3 
to the ‘Sambhav’ program by the coun lor/treating physician. Patients offered ‘Sambhav’ 4 
program included (a) All confirmed patients (age <60 years) for HCV requiring treatment (b) 5 
monthly documented income >INR 10000 (US$157). The other prerequisites for financial 6 
assistance included (i) one loan per family; (ii) minimum amount of loan INR 100000 (US$1565); 7 
(iii) payment of an interest if loan repayment tenure was more than 2-4 years. The exclusion criteria 8 
were (a) age >60 years (b) single patients (widow/widower, divorcee) and (c) monthly documented 9 
income <INR 10000 (US$157).  10 
 11 
 12 
Financer 
Patient Clinic  Counsellor  
Visit, 
check-up 
Refer 
patients 
1 2 
Refer 
patients 
3 Apply for 
loan* 
4 
Patient Distributor   
Financer 
Give voucher 3 
Pays EMI 
monthly 
1 
Provide loan in 
form of voucher 
2 
Give  
vial 
4 
Clinic  
Counsellor  
Face-to-face 
counselling; Tx 
administration 
5 
Check-up, 
testing 
6 
Figure. Depicting the Flow of Patient Enrolment, loan Sanction and Follow up in Sambhav Program.
Sood et al
International Journal of Health Policy and Management, 2018, 7(12), 1138–1144 1141
‘Sambhav’ program, 106 (45.4%) received the financial 
assistance. The applications of remaining 127 patients were 
rejected due to various reasons (age >60 years [05/127, 
3.9%], low income [52/127, 40.9%], non-compliance after the 
initiation of loan process [70/127, 55.1%]). 
Among the patients who applied for the ‘Sambhav’ program, 
the rate of treatment initiation was higher (93/106, 87.7%) 
in patients who got financial assistance as compared to the 
patients who paid for the treatment by themselves due to 
failure to enroll in the ‘Sambhav’ program (52/127, 42.5%, P 
<.001).
In 2013, a total of 344 patients were treated with Peg-INF 
aipha and RBV. Of the 344 patients only 145/344 (42.5%) 
had applied for Sambhav program while 57.5% (199/344) 
did not apply for this novel initiative. However more patients 
(145/233, 62.2% vs. 199/353, 56.5%) initiated treatment 
when exposed to Sambhav initiative (Table 3). Thus, the 
introduction of ‘Sambhav’ program increased the likelihood 
of treatment initiated by an odds ratio of 10 (Tables 4 and 5).
The loan was waived of in 12/93 (12.9%) patients loan as 
they did not respond to drugs at 12 weeks (failed rapid 
virological response, RVR). The treatment compliance rate 
also improved with the financial help and counseling from 
the ‘Sambhav’ program (87.1% with ‘Sambhav’ vs. 74.1% 
without ‘Sambhav’). On bivariate analysis between 2012 and 
2013 the odds ratio for the SAMBHAV interest free loan after 
controlling for the patients’ socio-economic status indicates 
likelihood of increase in the compliance by nearly 4 times 
(Tables 6 and 7).
Discussion
In 2013, 585 patients were enrolled and offered ‘Sambhav’ 
assistance and the treatment initiation and compliance rates 
were compared with 2012 group (n = 628) when ‘Sambhav’ 
was not available. Of the 233 patients (39.8%) who applied 
for ‘Sambhav’ program, 45.4% (106/233) received the 
assistance while 127 applications were rejected due to various 
reasons. There was a significant difference between the two 
groups in HCV treatment initiation (51% in 2012 and 59% 
in 2013) (P = .004). A majority 87.7% (93/106) of the patients 
who received ‘Sambhav’ assistance initiated the treatment 
compared to only 42.5% (52/127) among those who were 
offered ‘Sambhav’ support but did not get it due to various 
reasons. The compliance rates were also better (87.7% vs. 
74.1%) when compared groups with and without ‘Sambhav’ 
support.
HCV related liver diseases are major healthcare burden in 
Punjab. There are many patient, provider, government and 
payer factors which effectively prevent delivery of HCV care. 
Patient-related factors are a common source of treatment 
deferral and include limited awareness, poor compliance to 
physician recommendations, economic or social pressures, 
treatment fears, psychiatric disease and injection drug 
use. Specific factors identified as barriers to medication 
compliance among patients with low socioeconomic status 
were high medication costs and poor understanding of 
medication instructions. Also, the patients lack knowledge 
about the urgency of the initiating therapy, adverse events and 
existence of cure for this disease with successful treatment. 
There is stigma and many myths associated with HCV, 
leading patients seeking alternative remedies through quacks. 
Therefore, these patients need counseling about various 
aspects of disease and therapy.5-7
In India, a majority of the financial assistance is provided by 
the banks but recently NBFC’s are becoming popular among 
Table 1. Baseline Patient Characteristics
Variable(s) Group = 2012 (n = 628) 
Group = 2013
 (n = 585) 
Age (y) (mean ± SD) 43.1 ± 13.2 42.9 ± 11.7 
Height (cm) (mean ± SD) 168.6 ± 8.2 168.4 ± 8.4 
Weight (kg) (mean ± SD) 70.1 ± 14.2 70.1 ± 13.4 
Gender, No. (%) 
Male 422 (67.2) 391 (66.8) 
Female 206 (32.8) 194 (33.2) 
Education, No. (%) 
Elementary education 241 (38.4) 192 (32.8) 
Secondary 304 (48.4) 307 (52.5) 
Graduate and above 83 (13.2) 86 (14.72) 
Monthly Income, No. (%) 
<10K 255 (40.6) 135 (23.1) 
10-25K 255 (40.6) 293 (50.1) 
>25K 112 (17.8) 151 (25.8) 
Missing data 06 (1.0) 06 (1.0) 
Occupation, No. (%) 
Unemployed 230 (36.6) 189 (32.3) 
Farmer and shop owner 331 (52.7) 335 (57.3) 
White-collar jobs 63 (10.0) 59 (10.1) 
Missing data 04 (0.6) 02 (0.3) 
Alcohol consumption, No. (%) 180 (28.7) 174 (29.7) 
Drug abuse, No. (%) 43 (6.8) 45 (7.7) 
Smokers, No. (%) 09 (1.4) 36 (6.2) 
Table 2. Treatment Initiation Duration and Compliance
Variable (s) Group = 2012 (N=628
Group = 2013 
(N=585) P Value 
Patients initiating treatment, 
No. (%) 
318 (50.6) 344 (58.8) <.001a 
Treatment duration (wk), 
(mean ± SD) 
25.9 ± 10.5 26.7 ± 10.6 >.5b 
Treatment compliance (%) 233/318 (73.3) 271/344 (78.8) >.05 
a Based on chi-square test.
b Based on independent t test.
Table 3. Treatment Initiation as Compliance in Patients Applying for 
Financial Assistance (Group = 2013)
Financial 
Assistance 
Granted (n = 106)
Financial 
Assistance Not-
granted (n = 127)
P 
Value
Started treatment, 
(n = 233) No. (%)
93 (87.7) 54 (42.5) <.001
Treatment compliance, 
(n = 147) No. (%)
81 (87.1) 40 (74.1) <.05 
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the general public and loan seekers. The banks in India are 
incorporated by the Banking Companies Act, whereas NBFCs 
are incorporated by the Companies Act of 1956. NBFCs can 
just make investment or lend, they do not accept demand 
deposits. But when it comes to borrowing loan most prefer 
NBFCs over banks and the reason for this is banks have hard 
rules and require more time to approve or sanction a loan. 
On the other hand, NBFCs ensure quicker processing and 
necessary loan amount is disbursed within days. Though rate 
of interest is high at NBFCs most of the times as compared 
to banks, borrowers still prefer to take loans from NBFC 
considering the ease of getting loan and lesser complications. 
Moreover, individuals with poor credit rating are considered 
to be high-risk and generally do not get loans from banks. 
Unless the credit score is above 600-650, it is very difficult 
to get a loan sanctioned from banks. NBFCs on the other 
hand offer loans to individuals with low credit score and 
have brought down the interest rates to either equal to bank 
lending rates or at times even lower than that.3,4,7 Thus, with 
all the other benefits when rate of interest is also lowered, 
and borrowers find this easier and affordable. This has also 
resulted in lower EMI for the borrowers. 
In 2012, Merck & Co. launched its pilot Hepatitis Financing 
Mechanism, or ‘Sambhav’ Program in the state of Punjab in 
India. Market research revealed that many patients could not 
afford the cost of treatment for hepatitis C. So in response, for 
patients with limited or no insurance coverage, the company 
developed an innovative financing model for its hepatitis 
C treatment in high prevalence areas for HCV infection in 
North India. This novel program had two components: free 
counselor services for disease management and financing by 
way of loan. Under the financing program, eligible patients 
Table 4. Logistic Regression (Patient Initiating Treatment as Dependent Variable)
B SE Wald df P Value Exp (B)
Age 0.000 0.016 0.000 1 1.000 1.000
Gender 0.227 0.605 0.140 1 .708 1.254
Residential status (0=U/1=R) -0.806 0.462 3.051 1 .081 0.447
Education score (0 = elementary education) - - 1.843 2 .398 -
Education score (1 = secondary) 1.068 0.799 1.788 1 .181 2.910
Education score (2 = ≥ graduate) 0.671 0.681 0.970 1 .325 1.956
Monthly income (0 = <10K) - - 13.259 2 .001 -
Monthly income (1 = 10-25K) -2.337 0.647 13.048 1 .000 0.097
Monthly income (2 = >25K) -1.674 0.562 8.871 1 .003 0.188
Occupation score (0 = Unemployed) - - 1.295 2 .523 -
Occupation score (1 = shopown and farmers) 0.872 0.969 0.811 1 .368 2.392
Occupation score (2 = white-collar jobs) 0.207 0.838 0.061 1 .804 1.231
Family history (0=N/1=Y) 0.434 0.414 1.100 1 .294 1.544
Loan application accepted (0=N/1=Y) 2.350 0.412 32.522 1 .000 10.489
Constant 0.498 1.010 0.243 1 .622 1.646
Abbreviation: SE, standard error.
Table 5. Variables in the Equation With Respect to Table 4
B SE Wald df P Value Exp(B)
95% CI for EXP(B)
Lower Upper
Step 1
Age 0.000 0.016 0.000 1 1.000 1.000 0.968 1.033
Gender (1) -0.227 0.605 0.140 1 .708 0.797 0.243 2.611
Residential status (1) 0.806 0.462 3.051 1 .081 2.239 0.906 5.534
Education score - - 1.843 2 .398 - - -
Education score (1) 1.068 0.799 1.788 1 .181 2.910 0.608 13.927
Education score (2) 0.671 0.681 0.970 1 .325 1.956 0.515 7.435
Monthly income - - 13.259 2 .001 - - -
Monthly income (1) -2.337 0.647 13.048 1 .000 0.097 0.027 0.343
Monthly income (2) -1.674 0.562 8.871 1 .003 0.188 0.062 0.564
Occupation score - - 1.295 2 .523 - - -
Occupation score (1) 0.872 0.969 0.811 1 .368 2.392 0.358 15.968
Occupation score (2) 0.207 0.838 0.061 1 .804 1.231 0.238 6.357
Family history (1) -0.434 0.414 1.100 1 .294 0.648 0.288 1.458
Accepted YN (1) -2.350 0.412 32.522 1 .000 0.095 0.043 0.214
Constant 2.703 0.949 8.107 1 .004 14.927 - -
Abbreviations: SE, standard error; YN, yes/no.
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get interest free, unsecured financing from NBFC, for the 
treatment of hepatitis C and counselor services were rendered 
to address various concerns and myths of patients regarding 
therapy and disease. This was a unique collaboration between 
a hospital/clinic, pharmaceutical company and financing 
institution to develop a new business model to address a 
major unmet patient need – access to medicines by reducing 
cash flow burden. The benefits of providing financial support 
were observed as more number of patients initiated treatment.
The ultimate aim of any prescribed medical therapy is to achieve 
certain desired outcomes in the patients concerned. These 
desired outcomes are part and parcel of the objectives in the 
management of the diseases or conditions. However, despite 
all the best intention and efforts on the part of the healthcare 
professionals, those outcomes might not be achievable if the 
patients are non-compliant.9-11 This shortfall may also have 
serious and detrimental effects from the perspective of disease 
management. Hepatitis C infection is a chronic liver disease 
requiring treatment for longer duration and regular follow 
ups with their treating physicians. Moreover, continuous 
motivation is required to start treatment considering the 
social stigma the HCV carries along with it especially in 
North India. The ‘Sambhav’ program provided counselor 
services through its project Saarthi which lead to statistically 
significant (P = .001) difference in the treatment compliance 
between those who received ‘Sambhav’ assistance and those 
who did not (87% among those who received compared to 
74% those who did not). It may be recalled that the impact 
of ‘Sambhav’ program on the compliance was not significant 
when we did not differentiate between those actually received 
the financial assistance and those who did not. This fact 
highlights the importance of counselor services which allow 
Table 6. Logistic Regression (Compliance to Treatment as Dependent Variable)
B SE Wald df P Value Exp (B)
Age -0.060 0.024 6.223 1 .13 0.941
Gender 1.562 0.895 3.046 1 .081 4.767
Residential status (0=U/1=R) 0.746 0.567 1.733 1 .188 2.108
Education score (0 = elementary education) - - 2.941 2 .230 -
Education score (1 = secondary) 0.316 1.112 0.081 1 .776 1.371
Education score (2 = ≥ graduate) -0.713 0.950 0.565 1 .452 0.490
Monthly income (0 = <10K) - - 0.743 2 .690 -
Monthly income (1 = 10-25K) 0.020 0.915 0.001 1 .982 1.021
Monthly income (2 = >25K) -0.465 0.612 0.578 1 .447 0.628
Occupation score (0 = Unemployed) - - 3.965 2 .138 -
Occupation score (1 = shopown and farmers) 1.990 1.202 2.742 1 .098 7.312
Occupation score (2 = white-collar jobs) 0.258 1.000 0.067 1 .796 1.294
Family history (0=N/1=Y) -0.287 0.591 0.236 1 .627 0.751
Loan application accepted (0=N/1=Y) 1.262 0.542 5.417 1 .020 3.532
Constant 1.980 1.371 2.086 1 .149 7.242
Abbreviations: SE, standard error; YN, yes/no.
Table 7. Variables in the Equation With Respect to Table 6
B SE Wald df P Value Exp(B)
95% CI for EXP(B)
Lower Upper
Step 1
Age -0.060 0.024 6.223 1 .013 0.941 0.898 0.987
Gender (1) -1.562 0.895 3.046 1 .081 0.210 0.036 1.212
Residential status (1) -0.746 0.567 1.733 1 .188 0.474 0.156 1.440
Education score - - 2.941 2 .230 - - -
Education score (1) 0.316 1.112 0.081 1 .776 1.371 0.155 12.127
Education score (2) -0.714 0.950 0.565 1 .452 0.490 0.076 3.150
Monthly income - - 0.743 2 .690 - - -
Monthly income (1) 0.020 0.915 0.001 1 .982 1.021 0.170 6.131
Monthly income (2) -0.465 0.612 0.578 1 .447 0.628 0.189 2.084
Occupation score - - 3.965 2 .138 - - -
Occupation score (1) 1.990 1.202 2.742 1 .098 7.312 0.694 77.063
Occupation score (2) 0.258 1.000 0.067 1 .796 1.294 0.182 9.197
Family history (1) 0.287 0.591 0.236 1 .627 1.332 0.418 4.243
Accepted YN (1) -1.262 0.542 5.417 1 .020 0.283 0.098 0.819
Constant 5.263 1.480 12.641 1 .000 192.966 - -
Abbreviations: SE, standard error; YN, yes/no.
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patients to understand the disease better, treatment related 
myths are attended; patients are kept motivated to continue 
treatment, and are also made aware of any therapy related side 
effects.
Conclusion
HCV is prevalent in Northern India especially in the state 
of Punjab. Financial constraints and lack of knowledge are 
the barriers for not seeking treatment leading to serious 
liver diseases. As a response to this, an innovative program 
was initiated in high prevalence states including Punjab 
not only to provide unsecured interest free loan and also 
disease management. The treatment initiation rate of the 
HCV increased and treatment compliance also improved 
significantly when provided the ‘Sambhav’ support. In this 
context, the ‘Sambhav’ program experience has important 
implications for policy development.
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